Evidence mapPaperPMID 25883166Full record

Trial reportJournal of diabetes science and technology2015

Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes: Injection Site Warming to Improve Glycemic Control.

Itamar Raz, Gabriel Bitton, Dmitry Feldman, Tal Alon, Andreas Pfutzner, William V Tamborlane

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of diabetes science and technology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Modeling the acute effects of exercise on insulin kinetics in type 1 diabetes.Journal of pharmacokinetics and pharmacodynamics · 2018
    Article
  3. Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Itamar RazDepartment of Medicine, Diabetes Unit, Hadassah University Hospital, Jerusalem, Israel ntv502@netvision.net.il.
Gabriel BittonInsuline Medical Ltd, Petach Tikva, Israel.
Dmitry FeldmanInsuline Medical Ltd, Petach Tikva, Israel.
Tal AlonInsuline Medical Ltd, Petach Tikva, Israel.
Andreas PfutznerDiabetes Center and Practice, Mainz, Germany Insuline Medical Ltd, Pfützner Science & Health Institute, Mainz, Germany.
William V TamborlaneDepartment of Pediatrics, Yale School of Medicine, New Haven, CT, USA.
Hadassah Academic College · ILYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDelays in the time-action profiles of premeal boluses of rapid-acting insulin analogs contribute to early postmeal hyperglycemia in patients with diabetes. We tested whether applying local heat to skin around the injection site to increase the rate of insulin absorption reduces postprandial hyperglycemia in patients with type 2 diabetes.

methodsFourteen patients with type 2 diabetes (4 females; age 61.6 ± 8.4 years, HbA1c 8.42 ± 1.13%; BMI 29.10 ± 5.61 kg/m(2)) on intensified insulin therapy underwent 5-hour meal tolerance tests (MTTs) with a standardized liquid meal after an overnight fast on 2 study days. Subjects injected 0.2 U/kg of insulin aspart or lispro subcutaneously into the abdominal skin on both days with and without the use of the InsuPad device.

resultsFollowing the premeal bolus injection of rapid-acting insulin analog, infusion site warming led to a rise in plasma insulin levels to peak concentrations that were significantly earlier than without skin warming (mean ± SD 52 ± 26.7 vs 80 ± 51.3 minutes, P < .005) as well as increase in plasma insulin levels during the first hour after injection (mean ± SD 63.5 ± 32.7 IU vs 48.0 ± 25.0 uU.min/ml, P = .019). As a result, the area under the curve of the postprandial glucose excursion during the first 2 hours (the primary study outcome) and the entire 5 hours after the meal were significantly reduced (P = .007 and P = .03, respectively) with skin warming around the injection site. DISCUSSION AND

conclusionsUse of the InsuPad to increase the rate of insulin absorption provides an effective means to achieve better control of postmeal glucose excursions in type 2 diabetic patients receiving premeal injections of rapid-acting insulin analogs.

Indexed as

Insulin Infusion SystemsAdolescentAdultAgedBlood GlucoseCross-Over StudiesDiabetes Mellitus, Type 1FemaleGlucose Tolerance TestGlycated HemoglobinHumansHyperglycemiaHypoglycemic AgentsInfusions, SubcutaneousInsulinMaleBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinglucose controlhyperglycemiapostprandialwarming device

Identifiers

PMID25883166
PMCPMC4604546
OpenAlexW2083642808

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.